Coronary artery diseaseSafety, feasibility, and diagnostic accuracy of accelerated high-dose dipyridamole stress echocardiography
Section snippets
Patient population
Between April 1997 and April 1999, 1,295 nonconsecutive in-hospital patients or outpatients referred to the echocardiographic laboratory for evaluation of chest pain, or patients with known coronary artery disease, or both, were enrolled in the study. Exclusion criteria were congestive heart failure, unstable angina, or documented cardiomyopathy. Patients with second- or third-degree atrioventricular block or with sick sinus syndrome and severe asthmatic or chronic obstructive pulmonary disease
Feasibility and safety
The feasibility and safety analysis was performed on the total population of 1,295 patients, whereas the evaluation of diagnostic accuracy was evaluated in the subset of 216 patient with independently acquired angiographic information. The total laboratory time (from patient arrival to written report) was around 30 minutes.
Hemodynamic variables
Heart rate, systolic and diastolic blood pressure, and rate-pressure products both at baseline and at peak stress are presented in Table 1.
Stress tolerability
Echocardiographic studies were
Discussion
Accelerated high-dose dipyridamole is a highly feasible, reasonably well tolerated and accurate test in patients with known or suspected coronary artery disease. Its main advantage over the currently accepted version of high-dose testing is that it reduces imaging and laboratory time by almost 50%, with obvious favorable impact on logistics and costs.
References (22)
- et al.
Dipyridamole-echocardiography test in effort angina pectoris
Am J Cardiol
(1985) - et al.
High dose dipyridamole echocardiography test in effort angina pectoris
J Am Coll Cardiol
(1986) - et al.
Stress echocardiographyrecommendations for performance and interpretation of stress echocardiography. Stress Echocardiography Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography
Am Soc Echocardiogr
(1998) - et al.
The atropine factor in pharmacological stress echocardiography
J Am Coll Cardiol
(1996) - et al.
Safety of dipyridamole testing in 73,806 patientsthe multicenter dipyridamole safety study
J Nucl Cardiol
(1995) - et al.
Enhanced sensitivity for detection of coronary artery disease by addiction of atropine to dipyridamole echocardiography
Eur Heart J
(1993) - et al.
ACC/AHA guidelines for the clinical application of echocardiographya report of the American College of Cardiology/American Heart Association Task Force on practice Guidelines (Committee on Clinical Application of Echocardiography), developed in collaboration with the American Society of Echocardiography
Circulation
(1997) - et al.
Pharmacological stress echocardiography in the diagnosis of coronary artery disease and myocardial ischemiaa comparison between dobutamine and dipyridamole
Eur Heart J
(1992) - et al.
Dipyridamole and dobutamine-atropine stress echocardiography in the diagnosis of coronary artery diseasecomparison with exercise stress test, analysis of agreement and impact of antianginal treatment
Chest
(1996) - et al.
Accelerated high-dose dipyridamole stress-echo, the busy cardiologist’s stress test
Eur Heart J
(1998)
Dipyridamole-echocardiography testthe historical background and the physiologic basis
Eur Heart J
Cited by (48)
Prognostic Value of Heart Rate Reserve in Patients with Permanent Atrial Fibrillation during Dipyridamole Stress Echocardiography
2020, American Journal of CardiologyCitation Excerpt :Transthoracic SE studies were performed with commercially available ultrasound machines depending on the possibilities and the equipment available in each period. High-dose dipyridamole (up to 0.84 mg/kg over 10 minutes up to 200212 and over 6 minutes thereafter) SE was performed according to well-established protocols.2 Wall motion score index (WMSI) was derived by dividing the sum of individual segment scores by the number of interpretable segments in a 17-segment model of the left ventricle.2,3
Prognostic value of heart rate reserve is additive to coronary flow velocity reserve during dipyridamole stress echocardiography
2020, Archives of Cardiovascular DiseasesAge- and Gender-Specific Prognostic Cutoff Values of Coronary Flow Velocity Reserve in Vasodilator Stress Echocardiography
2019, Journal of the American Society of EchocardiographyUsefulness of Blunted Heart Rate Reserve as an Imaging-Independent Prognostic Predictor During Dipyridamole Stress Echocardiography
2019, American Journal of CardiologyCitation Excerpt :This finding has been consistently observed with adenosine,9 dipyridamole,10 and A2A receptor adenosine agonist regadenoson.26 The present study is the first one with echocardiography, which is different from perfusion scintigraphy (SPECT) since ischemia is the required end point, and is the first one with the high dose, which is the standard for echocardiography imaging.5,6 Association of chronotropic incompetence with events was present also in patients on β blockers,27 as previously reported with exercise28 and dipyridamole perfusion imaging stress.11
Accelerated dobutamine stress testing: Feasibility and safety in patients with moderate aortic stenosis
2015, Egyptian Heart Journal